•Association of bowel urgency, disease activity and disability in patients with inflammatory Bowel Disease: A cross-sectional study from the GETAID
•Chronic stress at the crossroads: Decoding the HPA-SAM-immune-gut axis in inflammatory bowel disease pathogenesis and therapeutics
•Oral nanoarray hydrogel-mediated macrophage repolarization and ferroptosis suppression for inflammatory bowel disease treatment
•The Efficacy and Safety of Etrasimod in Mildly to Moderately Active Ulcerative Colitis: Results from the Phase 2 GLADIATOR Trial
•Distinct predictive factors for acute severe ulcerative colitis in East Asian and Western populations
